Virtual biotech Antiva sets out on a big R&D quest, armed with a $22M round for an HPV therapy
For a virtual biotech with one drug just entering the clinic, little South San Francisco-based Antiva Biosciences has carved out a very big mission for itself.
Led by ex-BayBio chief Gail Maderis, the biotech is targeting precancerous lesions caused by HPV with an experimental topical therapy. They’ve mapped out a clinical development plan that can, in a relatively short period of time, offer some solid evidence of its potential. And this morning their venture syndicate has come up with a $22 million round designed to provide enough support to land key data readouts.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.